Fraud & Corruption in the Pharmaceutical Industry in China

Despite increased enforcement of the US Foreign Corrupt Practices Act ("FCPA") and China's own commercial bribery laws, fraud and corruption remains rife across many industries in China, especially in the pharmaceutical and life sciences industry where the benefits of bribery still seem to outweigh the risks. The most common typologies being:  Sales teams bribing doctors to purchase their products
Fictitious sales and fake contracts
Tendering fraud and bid rigging
Off label use of pharmaceuticals​